A Phase 1b/2, Open Label, Dose Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf 06463922 In Patients With Advanced Or Metastatic Non Small Cell Lung Cancer

Trial Profile

A Phase 1b/2, Open Label, Dose Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf 06463922 In Patients With Advanced Or Metastatic Non Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Avelumab (Primary) ; Crizotinib; Lorlatinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Javelin Lung 101
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Planned End Date changed from 13 Jan 2018 to 14 Jan 2018.
    • 06 Jun 2017 Planned primary completion date changed from 13 Jan 2018 to 14 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top